Lytix Biopharma AS announced that the Research Council of Norway has approved Lytix?s application for up to NOK 14.3 million (USD 1.3 million) of non-dilutive financial support from the ?SkatteFUNN? R&D tax incentive scheme for a project in respect of its lead program: ?Intratumoral LTX-315 in advanced melanoma?. The approval gives Lytix the right to claim tax deductions for relevant and documentable costs related to research and development activities in the approved project for the period 2023 to 2025 inclusive.

The main objective of the project is to assess the safety and efficacy of LTX-315 in patients with advanced melanoma that are refractory to treatment with Immune Checkpoint Inhibitors. This will be assessed in a Phase II trial that will enroll up to 40 patients at study sites in the US and Europe (including Norway).